Day: November 22, 2021
Resource for journalists around the world on COVID-19 vaccines
covidvaccinehub.org (https://covidvaccinehub.org/) If you’re a fact checker or a journalist, we’re here to help you find the information and experts you need for your story. SYDNEY, Nov. 22, 2021 /PRNewswire/ — The COVID-19 Vaccine Media Hub (https://covidvaccinehub.org/) is a dedicated global resource for journalists and fact checkers wanting access to evidence-based information on COVID-19 vaccines […] …
Enernet Global acquires KPS Power Africa
Distributed energy service company accelerates presence in Africa with acquisition of African subsidiary of KPS Australia NEW YORK, Nov. 22, 2021 (GLOBE NEWSWIRE) — Enernet Global Inc. (“Enernet”), a distributed energy service company whose mission is to decarbonise the world’s supply chains, acquired KPS Power Africa (“KPSPA”) to accelerate presence in African mining. Enernet’s global footprint […] …
Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor
Xencor receives rights to additional equity in Zenas as upfront payment and is eligible for up to $480 million in potential milestone payments and royalties on net sales of commercialized products Obexelimab is a novel bifunctional antibody with first-in-class potential to treat autoimmune diseases MONROVIA, Calif., HONG KONG and BOSTON, Nov. 21, 2021 (GLOBE NEWSWIRE) […] …
Zenas BioPharma Adquire Direitos Mundiais Exclusivos do Obexelimab da Xencor
Xencor recebe direitos sobre ações adicionais da Zenas como pagamento antecipado e é elegível para até US$ 480 milhões em pagamentos de marcos potenciais e royalties sobre vendas líquidas de produtos comercializados O obexelimab é um novo anticorpo biespecífico com potencial de primeira classe para tratar doenças autoimunes MONROVIA, Califórnia, HONG KONG e BOSTON, Nov. […] …
Zenas BioPharma acquiert des droits mondiaux exclusifs sur l’Obexelimab auprès de Xencor
Xencor reçoit des droits sur des capitaux propres supplémentaires dans Zenas en tant que paiement initial et est éligible à un maximum de 480 millions de dollars en paiements échelonnés potentiels et redevances sur le chiffre d’affaires net des produits commercialisés L’Obexelimab est un nouvel anticorps bispécifique avec un potentiel de premier ordre pour traiter les […] …